Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
6.91
+0.05 (0.73%)
At close: Dec 5, 2025, 4:00 PM EST
6.89
-0.02 (-0.29%)
After-hours: Dec 5, 2025, 7:59 PM EST
Novavax Revenue
Novavax had revenue of $70.45M in the quarter ending September 30, 2025, a decrease of -16.64%. This brings the company's revenue in the last twelve months to $1.06B, up 20.27% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.06B
Revenue Growth
+20.27%
P/S Ratio
1.05
Revenue / Employee
$1,118,331
Employees
952
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NVAX News
- 4 days ago - FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
- 4 days ago - Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men - Market Watch
- 4 days ago - Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barrons
- 16 days ago - Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 23 days ago - Shah Capital pushes for Novavax sale, warns of proxy fight - Reuters
- 23 days ago - Novavax to Participate in Jefferies London Healthcare Conference - PRNewsWire
- 4 weeks ago - Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire